YTX-7739 is under clinical development by Kineta and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect YTX-7739’s likelihood of approval (LoA) and phase transition for Parkinson’s Disease took place on 06 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their YTX-7739 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

YTX-7739 overview

YTX-7739 is under development for the treatment of Parkinson's disease and glioblastoma multiforme (GBM). It is administered orally. The drug candidate is withaferin A analogue. The drug candidate is developed based on Company’s three integrated platforms which includes ultra high-throughput phenotypic screening (uHTS) platforms, human neuronal platform and drug-target identification platform. The therapeutic candidate acts by targeting stearoyl CoA desaturase. The drug candidate is also under development for the treatment of Lewy Body Dementia.

Kineta overview

Yumanity Therapeutics Inc (Yumanity), formerly Proteostasis Therapeutics Inc, is a clinical stage development company focused on the development of treatments for neurodegenerative diseases. The company uses its drug discovery platform for the development of its pipeline products. Yumanity’s pipeline product candidates include YTX-7739 for the treatment of Parkinson’s disease; YTX-9184 for the treatment of dementia with lewy bodies. Other pipeline also comprises of additional programs with undisclosed product candidates that are focused on frontotemporal lobar dementia (FTLD), amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. Yumanity is headquartered in Boston, Massachusetts, the US.

Quick View YTX-7739 LOA Data

Report Segments
  • Innovator
Drug Name
  • YTX-7739
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Oncology
Key Developers
  • Sponsor Company: Kineta
  • Originator: University of Arizona
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.